Loading...

We've got a brand new version of Simply Wall St! Try it out

BIO-key International

Nasdaq:BKYI
Snowflake Description

Fair value with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BKYI
Nasdaq
$7M
Market Cap
  1. Home
  2. US
  3. Software
Company description

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, and related identity management and credentialing biometric hardware and software solutions. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
  • BIO-key International has significant price volatility in the past 3 months.
BKYI Share Price and Events
7 Day Returns
-5.6%
NasdaqCM:BKYI
2.5%
US Software
0.7%
US Market
1 Year Returns
-56.9%
NasdaqCM:BKYI
32.7%
US Software
13.7%
US Market
BKYI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BIO-key International (BKYI) -5.6% -20.3% -37.8% -56.9% -83% -79.7%
US Software 2.5% 9.9% 4.7% 32.7% 116.8% 154.3%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • BKYI underperformed the Software industry which returned 32.7% over the past year.
  • BKYI underperformed the Market in United States of America which returned 13.7% over the past year.
Price Volatility
BKYI
Industry
5yr Volatility vs Market
Related Companies

Value

 Is BIO-key International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BIO-key International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BIO-key International.

NasdaqCM:BKYI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:BKYI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Software Unlevered Beta Simply Wall St/ S&P Global 1.13
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.126 (1 + (1- 21%) (33.54%))
1.284
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.28
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.284 * 5.96%)
10.39%

Discounted Cash Flow Calculation for NasdaqCM:BKYI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BIO-key International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:BKYI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.39%)
2020 -0.90 Analyst x1 -0.82
2021 0.30 Analyst x1 0.25
2022 0.52 Est @ 72.34% 0.38
2023 0.78 Est @ 51.46% 0.53
2024 1.07 Est @ 36.84% 0.65
2025 1.36 Est @ 26.61% 0.75
2026 1.62 Est @ 19.44% 0.81
2027 1.85 Est @ 14.43% 0.84
2028 2.06 Est @ 10.92% 0.85
2029 2.23 Est @ 8.46% 0.83
Present value of next 10 years cash flows $5.00
NasdaqCM:BKYI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $2.23 × (1 + 2.73%) ÷ (10.39% – 2.73%)
$29.94
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $29.94 ÷ (1 + 10.39%)10
$11.14
NasdaqCM:BKYI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $5.00 + $11.14
$16.14
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $16.14 / 14.41
$1.12
NasdaqCM:BKYI Discount to Share Price
Calculation Result
Value per share (USD) From above. $1.12
Current discount Discount to share price of $0.51
= -1 x ($0.51 - $1.12) / $1.12
54.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BIO-key International is available for.
Intrinsic value
>50%
Share price is $0.51 vs Future cash flow value of $1.12
Current Discount Checks
For BIO-key International to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BIO-key International's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BIO-key International's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BIO-key International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BIO-key International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:BKYI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.46
NasdaqCM:BKYI Share Price ** NasdaqCM (2019-11-18) in USD $0.51
United States of America Software Industry PE Ratio Median Figure of 71 Publicly-Listed Software Companies 44.43x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BIO-key International.

NasdaqCM:BKYI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BKYI Share Price ÷ EPS (both in USD)

= 0.51 ÷ -0.46

-1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIO-key International is loss making, we can't compare its value to the US Software industry average.
  • BIO-key International is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BIO-key International's expected growth come at a high price?
Raw Data
NasdaqCM:BKYI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
37.7%per year
United States of America Software Industry PEG Ratio Median Figure of 60 Publicly-Listed Software Companies 2.54x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BIO-key International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BIO-key International's assets?
Raw Data
NasdaqCM:BKYI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.49
NasdaqCM:BKYI Share Price * NasdaqCM (2019-11-18) in USD $0.51
United States of America Software Industry PB Ratio Median Figure of 214 Publicly-Listed Software Companies 5.84x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqCM:BKYI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BKYI Share Price ÷ Book Value per Share (both in USD)

= 0.51 ÷ 0.49

1.03x

* Primary Listing of BIO-key International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIO-key International is good value based on assets compared to the US Software industry average.
X
Value checks
We assess BIO-key International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Software industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Software industry average (and greater than 0)? (1 check)
  5. BIO-key International has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BIO-key International expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BIO-key International expected to grow at an attractive rate?
  • Unable to compare BIO-key International's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare BIO-key International's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • BIO-key International's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:BKYI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:BKYI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 37.7%
NasdaqCM:BKYI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 36.2%
United States of America Software Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Software Industry Revenue Growth Rate Market Cap Weighted Average 11.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:BKYI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:BKYI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 9 0 -2 1
2020-12-31 7 -1 -4 1
2019-12-31 5 -4 -6 1
NasdaqCM:BKYI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 3 -3 -6
2019-06-30 4 -2 -8
2019-03-31 4 -2 -8
2018-12-31 4 -2 -8
2018-09-30 5 -2 -7
2018-06-30 6 -2 -6
2018-03-31 6 -2 -6
2017-12-31 6 -2 -5
2017-09-30 5 -3 -6
2017-06-30 4 -3 -6
2017-03-31 4 -4 -5
2016-12-31 3 -4 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BIO-key International is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • BIO-key International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:BKYI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BIO-key International Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BKYI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
NasdaqCM:BKYI Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.46
2019-06-30 -0.56
2019-03-31 -0.61
2018-12-31 -0.73
2018-09-30 -0.68
2018-06-30 -0.66
2018-03-31 -0.82
2017-12-31 -0.76
2017-09-30 -0.98
2017-06-30 -0.94
2017-03-31 -0.90
2016-12-31 -0.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BIO-key International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BIO-key International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BIO-key International has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BIO-key International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BIO-key International's growth in the last year to its industry (Software).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BIO-key International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BIO-key International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BIO-key International's 1-year growth to the US Software industry average as it is not currently profitable.
Earnings and Revenue History
BIO-key International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BIO-key International Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BKYI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 3.45 -6.44 5.10 1.31
2019-06-30 3.73 -7.68 5.23 1.40
2019-03-31 3.75 -7.95 5.25 1.40
2018-12-31 4.04 -8.50 5.33 1.42
2018-09-30 5.38 -6.81 4.97 1.41
2018-06-30 5.59 -5.54 5.16 1.41
2018-03-31 5.73 -5.84 5.52 1.56
2017-12-31 6.30 -5.04 5.68 1.66
2017-09-30 4.95 -6.07 5.77 1.75
2017-06-30 4.43 -5.60 5.46 1.90
2017-03-31 3.96 -5.19 5.07 2.01
2016-12-31 2.98 -4.99 4.44 2.01
2016-09-30 2.95 -5.02 4.04 1.97
2016-06-30 3.19 -4.76 4.13 1.81
2016-03-31 5.04 -2.43 4.07 1.64
2015-12-31 5.26 -1.99 4.12 1.56
2015-09-30 4.54 -1.76 3.96 1.51
2015-06-30 5.16 -0.73 3.94 1.47
2015-03-31 3.29 -2.51 3.85 1.55
2014-12-31 4.01 -1.88 3.67 1.63
2014-09-30 3.38 -2.31 3.46 1.72
2014-06-30 2.53 -3.04 3.22 1.75
2014-03-31 2.55 -2.57 2.90 1.57
2013-12-31 1.99 -2.58 2.78 1.34
2013-09-30 3.14 -1.17 2.67 1.13
2013-06-30 3.12 -0.62 2.26 0.98
2013-03-31 3.23 -0.68 2.42 0.96
2012-12-31 3.84 0.00 2.29 0.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BIO-key International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BIO-key International has efficiently used its assets last year compared to the US Software industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BIO-key International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BIO-key International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Software industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BIO-key International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BIO-key International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BIO-key International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BIO-key International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BIO-key International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BIO-key International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BIO-key International Company Filings, last reported 1 month ago.

NasdaqCM:BKYI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 7.12 1.86 0.59
2019-06-30 8.07 0.54 0.69
2019-03-31 9.19 0.00 0.46
2018-12-31 10.47 0.00 0.32
2018-09-30 11.79 0.00 1.05
2018-06-30 11.46 0.00 0.30
2018-03-31 12.61 0.00 1.30
2017-12-31 13.75 0.00 0.29
2017-09-30 13.31 0.00 0.97
2017-06-30 13.41 0.00 0.99
2017-03-31 14.00 0.00 1.16
2016-12-31 15.45 0.00 1.06
2016-09-30 14.22 0.00 0.18
2016-06-30 15.40 0.00 2.01
2016-03-31 16.93 0.00 3.47
2015-12-31 18.15 0.00 4.32
2015-09-30 -0.28 0.71 0.07
2015-06-30 0.76 0.00 0.28
2015-03-31 -0.02 0.12 0.30
2014-12-31 0.76 0.00 0.84
2014-09-30 -0.26 0.00 0.17
2014-06-30 -0.24 0.00 0.52
2014-03-31 0.73 0.00 0.59
2013-12-31 1.05 0.00 2.02
2013-09-30 -0.95 0.50 0.23
2013-06-30 -1.19 0.50 0.10
2013-03-31 -0.66 0.50 0.45
2012-12-31 -1.22 0.32 0.08
  • BIO-key International's level of debt (26.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if BIO-key International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BIO-key International has less than a year of cash runway based on current free cash flow.
  • BIO-key International has less than a year of cash runway if free cash flow continues to reduce at historical rates of -68.9% each year.
X
Financial health checks
We assess BIO-key International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BIO-key International has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BIO-key International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BIO-key International dividends.
If you bought $2,000 of BIO-key International shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BIO-key International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BIO-key International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:BKYI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Software Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:BKYI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BIO-key International has not reported any payouts.
  • Unable to verify if BIO-key International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BIO-key International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BIO-key International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BIO-key International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BIO-key International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BIO-key International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BIO-key International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike DePasquale
COMPENSATION $333,101
AGE 64
TENURE AS CEO 16.8 years
CEO Bio

Mr. Michael W. DePasquale, also known as Mike, has been the Chief Executive Officer of BIO-key International Inc. since August 2006. Mr. DePasquale served as the Chief Executive Officer of BIO-key International from January 3, 2003 to July 2005 and Co-Chief Executive Officer from July 2005 to August 2006. He has more than 30 years of executive management, sales and marketing experience. Prior to BIO-key International Inc., he served as the President and Chief Executive Officer at Prism eSolutions, Inc since February 2001. From December 1999 to December 2000, Mr. DePasquale served as Group Vice President for WRC Media, a New York based distributor of supplemental education products and software. He served as Senior Vice President of Jostens Learning Corp., a California based provider of multi media curriculum, from January 1996 to December 1999. Prior to Jostes, he held sales and marketing management positions with McGraw-Hill and Digital Equipment Corporation. He has been the Chairman of BIO-key International Inc. since January 29, 2014. He has been a Director at BIO-key International Inc. since January 3, 2007. Mr. DePasquale earned a Bachelor of Science degree from the New Jersey Institute of Technology.

CEO Compensation
  • Mike's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mike's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BIO-key International management team in years:

8.2
Average Tenure
59
Average Age
  • The average tenure for the BIO-key International management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike DePasquale

TITLE
Chairman & CEO
COMPENSATION
$333K
AGE
64
TENURE
16.8 yrs

Ceci Welch

TITLE
Chief Financial Officer
COMPENSATION
$219K
AGE
59
TENURE
9.9 yrs

Mira LaCous

TITLE
Chief Technology Officer
COMPENSATION
$235K
AGE
57
TENURE
5.7 yrs

Scott Mahnken

TITLE
Vice President of Marketing
COMPENSATION
$156K
AGE
59
TENURE
8.8 yrs

Jim Sullivan

TITLE
Senior Vice President of Strategy & Business Development
AGE
52
TENURE
7.6 yrs

Fred Corsentino

TITLE
Chief Revenue Officer
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the BIO-key International board of directors in years:

3.9
Average Tenure
59
Average Age
  • The tenure for the BIO-key International board of directors is about average.
Board of Directors

Mike DePasquale

TITLE
Chairman & CEO
COMPENSATION
$333K
AGE
64
TENURE
5.8 yrs

Thomas Bush

TITLE
Independent Director
COMPENSATION
$10K
AGE
66
TENURE
5.8 yrs

Tom Gilley

TITLE
Independent Director
COMPENSATION
$9K
AGE
58
TENURE
5.8 yrs

Bob Michel

TITLE
Independent Director
COMPENSATION
$11K
AGE
62
TENURE
2.6 yrs

Kelvin Wong

TITLE
Director
COMPENSATION
$344K
AGE
56
TENURE
3.9 yrs

Jianhui Yao

TITLE
Director
COMPENSATION
$5K
AGE
47
TENURE
3.9 yrs

Pieter Knook

TITLE
Independent Director
COMPENSATION
$11K
AGE
60
TENURE
3.5 yrs

Fabian Shin

TITLE
Independent Director
COMPENSATION
$8K
AGE
50
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Nov 18 Buy Robert Michel Individual 28. Nov 18 28. Nov 18 5,000 $1.27 $6,350
X
Management checks
We assess BIO-key International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BIO-key International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Changing Sentiment Drive BIO-key International's (NASDAQ:BKYI) Share Price Down A Painful 74%?

Check out our latest analysis for BIO-key International BIO-key International isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last half decade, BIO-key International saw its revenue increase by 8.6% per year. … Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround.

Simply Wall St -

Is BIO-key International, Inc.'s (NASDAQ:BKYI) CEO Being Overpaid?

Check out our latest analysis for BIO-key International How Does Mike DePasquale's Compensation Compare With Similar Sized Companies? … We think total compensation is more important but we note that the CEO salary is lower, at US$275k. … If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at BIO-key International.

Simply Wall St -

BIO-key International, Inc. (NASDAQ:BKYI): Is Breakeven Near?

BIO-key International, Inc.'s (NASDAQ:BKYI):. … BIO-key International, Inc. … develops and markets fingerprint biometric identification and identity verification technologies, authentication-transaction security technologies, and related identity management and credentialing biometric hardware and software solutions.

Simply Wall St -

Does BIO-key International, Inc.'s (NASDAQ:BKYI) CEO Pay Matter?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mike DePasquale's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

How Much Of BIO-key International, Inc. (NASDAQ:BKYI) Do Insiders Own?

Every investor in BIO-key International, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … BIO-key International is not a large company by global standards.

Simply Wall St -

BIO-key International, Inc. (NASDAQ:BKYI): What Does Its Beta Value Mean For Your Portfolio?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

What does BIO-key International, Inc.'s (NASDAQ:BKYI) Balance Sheet Tell Us About Its Future?

(NASDAQ:BKYI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does BKYI's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Read This Before Selling BIO-key International, Inc. (NASDAQ:BKYI) Shares

So we'll take a look at whether insiders have been buying or selling shares in BIO-key International, Inc. … BIO-key International Insider Transactions Over The Last Year. … In total, BIO-key International insiders bought more than they sold over the last year

Simply Wall St -

Is BIO-key International Inc's (NASDAQ:BKYI) CEO Pay Fair?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mike DePasquale's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that BIO-key International Inc has a market cap of US$17m, and is paying total annual CEO compensation of US$843k

Simply Wall St -

BIO-key International Inc (NASDAQ:BKYI) Is Expected To Breakeven

BIO-key International Inc's (NASDAQ:BKYI):. … BIO-key International, Inc. … The US$17m market-cap posted a loss in its most recent financial year of -US$5m and a latest trailing-twelve-month loss of -US$6m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Company Info

Description

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, and related identity management and credentialing biometric hardware and software solutions. Its solutions enable application developers, value added resellers, and channel partners to integrate fingerprint biometrics into their applications. It offers ID Director, a solution for integration with CA Technologies / Broadcom’s Single Sign-on solution, Oracle’s Fusion Middleware SSO, IBM Tivoli Access Manager, as well as ISAM and other solutions. The company also provides Vector Segment Technology SDK, a biometric software development kit that provides developers the ability to incorporate its biometric capabilities into their respective product offerings or infrastructure; Intelligent Image Indexing, a biometric identification solution that offers one-to-many and one-to-one user identification; and Biometric Service Provider, which provides support for the BioAPI for a compliant interface to applications using biometrics for verification and identification. In addition, it offers WEB-key, an authentication-transaction security technology to conduct identification and identity verification transactions in unsecure environments, such as the world wide Web or off-site cloud environments. Additionally, the company develops and distributes hardware components; and sells third-party hardware components. BIO-key International, Inc. markets its products through its direct sales force, as well as through distributors, resellers, integrators, and partner networks to government and corporate customers primarily in North America. It has strategic partnership with Quantum Business Advisory to bring its software and hardware solutions to enterprises in India. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.

Details
Name: BIO-key International, Inc.
BKYI
Exchange: NasdaqCM
Founded: 1993
$7,348,358
14,408,546
Website: http://www.bio-key.com
Address: BIO-key International, Inc.
Building A,
Suite E,
Wall,
New Jersey, 07719,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BKYI Common Stock Nasdaq Capital Market US USD 24. Feb 1997
Number of employees
Current staff
Staff numbers
18
BIO-key International employees.
Industry
Systems Software
Software
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 23:34
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/18
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.